Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

45 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients.
Roth MD, Gitlitz BJ, Kiertscher SM, Park AN, Mendenhall M, Moldawer N, Figlin RA. Roth MD, et al. Among authors: gitlitz bj. Cancer Res. 2000 Apr 1;60(7):1934-41. Cancer Res. 2000. PMID: 10766183 Clinical Trial.
Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A. Tso CL, et al. Cancer Res. 2001 Nov 1;61(21):7925-33. Cancer Res. 2001. PMID: 11691814
Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A. Tso CL, et al. Cancer J. 2000 Jul-Aug;6(4):220-33. Cancer J. 2000. PMID: 11038142
Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P, Tso CL, Gitlitz B, Kaboo R, Hinkel A, Frand S, Kiertscher S, Roth MD, deKernion J, Figlin R, Belldegrun A. Mulders P, et al. Clin Cancer Res. 1999 Feb;5(2):445-54. Clin Cancer Res. 1999. PMID: 10037196
Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.
Mulders P, Tso CL, Pang S, Kaboo R, McBride WH, Hinkel A, Gitlitz B, Dannull J, Figlin R, Belldegrun A. Mulders P, et al. J Immunother. 1998 May;21(3):170-80. doi: 10.1097/00002371-199805000-00002. J Immunother. 1998. PMID: 9610908
Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, deKernion J, Belldegrun A. Figlin R, et al. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S92-7. Cancer J Sci Am. 1997. PMID: 9457402 Clinical Trial.
Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.
Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldawer N, Gitlitz B, deKernion J, Belldegrun A. Figlin RA, et al. J Urol. 1997 Sep;158(3 Pt 1):740-5. doi: 10.1097/00005392-199709000-00012. J Urol. 1997. PMID: 9258071 Clinical Trial.
Immunologic approaches to the treatment of cancer.
Figlin RA, Gitlitz BJ, Belldegrun A. Figlin RA, et al. Among authors: gitlitz bj. Cancer Invest. 1995;13(3):339-40. doi: 10.3109/07357909509094469. Cancer Invest. 1995. PMID: 7743386 No abstract available.
Dendritic cell-based immunotherapy of renal cell carcinoma.
Gitlitz BJ, Figlin RA, Pantuck AJ, Belldegrun AS. Gitlitz BJ, et al. Curr Urol Rep. 2001 Feb;2(1):46-52. doi: 10.1007/s11934-001-0025-9. Curr Urol Rep. 2001. PMID: 12084295 Review.
Vaccine and gene therapy of renal cell carcinoma.
Gitlitz BJ, Belldegrun AS, Figlin RA. Gitlitz BJ, et al. Semin Urol Oncol. 2001 May;19(2):141-7. Semin Urol Oncol. 2001. PMID: 11354534 Review.
45 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page